SHIKARI® Q-ADA


Enzyme immunoassay for the quantitative determination of free adalimumab (Humira®) in serum and plasma with confirmation.

The Matriks Biotek Shikari adalimumab ELISA has been especially developed for the quantitative analysis of free adalimumab in serum and plasma samples.



Click the diagram to see bigger

about-me



Required Volume (µl) 20
Total Time (min) 70
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 10
Spike Recovery (%) Between 85-115
Shelf Life (year) 1

SHIKARI® S-ATA


Enzyme immunoassay for the quantitative determination of antibodies to adalimumab in serum and plasma with confirmation.

Adalimumab (Humira®) was associated to the development of anti-Adalimumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Humira®. This might lead to severe complications. The Matriks Biotek Shikari® Antibody to Adalimumab ELISA Kit can be efficiently used for monitoring anti-Adalimumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Adalimumab antibodies.




Click the diagram to see bigger

about-me




Required Volume (µl) 20
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 30
Spike Recovery (%) Between 85-115
Shelf Life (year) 1

Total and Free Antibody to Adalimumab (Humira®) ELISA


Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to adalimumab in serum and plasma.

Free and Total Anti drug Antibody monitoring gained high importance along with measuring free drug from the patient samples. In order to make these measurements simple yet more informative. We have produced SHIKARI® S-ATA DUO to measure Free and Total anti drug antibodies to Adalimumab simultaniously on the same plate. The kit is semi-quantitative and enables follow up of the patients to adjust the dose of the drug and/or frequency of administration


If quantitative and confirmation is needed please refer to SHIKARI® S-ATAv2.





Click the graphic to see bigger

Click the schema to see bigger

Click the schema to see bigger




Required Volume (µl) 10
Total Time (min) 95
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 250
Spike Recovery (%) -
Shelf Life (year) 1
-->
   

PEER REVIEWED JOURNAL ARTICLES:

Ward, M. G., et al. "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease." Alimentary pharmacology & therapeutics 45.8 (2017): 1135-1145.
Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol. Apr;111(4):529-40, 2016.
Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.**
Bortlik M., et al., Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology, 2016 vol. 51, no. 2, 196–202.
Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. Sep;43(9):1018-23, 2016.**
Bodini G., Edoardo G. Giannini, Edoardo V. Savarino, and Vincenzo Savarino. Adalimumab Trough Levels and Response to Biological Treatment in Patients With Infl ammatory Bowel Disease: A Useful Cutoff in Clinical Practice. Am J Gastroenterol. Vol. 110, March, 2015.
Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol (2015) 50:758–768.
Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. **
Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov A.A., Cherkasova M.V., Nasonov E.L. EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY. Rheumatology Science and Practice. 52(6):624–630. 2014 Russian, English abstract
http://rsp.ima-press.net/rsp/article/view/2007
Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.
Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. **
Romero G., et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of AntiTNF-α. Macromol. Biosci. 13: (903–912), 2013.
Bortlik M et al, “Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study”, Scandinavian Journal of Gastroenterology. 48: 951–958, 2013
Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **

** Open Access


   

POSTER PRESENTATIONS:

Bodini G, et al, Correlation between Adalimumab trough serum concentration, Anti-Adalimumab antibodies and TNF-Alpha levels with clinical outcome in patients affected by Crohn’s disease,. United European Gastroenterology. Italy 2013.
Julsgaard M, et al, Time since last drug exposure in pregnancy determines Adalimumab and Infliximab levels in neonates(Era Study), Italy 2014
Szepes Z., et al, Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis, ECCO 2014 Inflammatory Bowel Disease.
Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha therapy(ERA study):Infliximab and adalimumab cord blood levels correlate with maternal levels at birth, ECCO 2014 Inflammatory Bowel Disease.
10  Goldberg R., et al, Predictors of sub-therapeutic infliximab oradalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions, ECCO 2014 Inflammatory Bowel Disease.

MATRIKS BIOTECHNOLOGY CO., LTD

Gazi Üniversitesi Gölbaşı Yerleşkesi Teknoplaza Binası,
(B Blok Zemin Kat BZ17),
06830,
Gölbaşı/ANKARA/TÜRKİYE

Contact Details

Telephone: +90 (312) 485 42 94
Intl.calls&Whatsapp: +90 (546) 485 42 94
Email: info@matriksbiotek.com
Email: order@matriksbiotek.com
Fax: +90 (312) 485 11 87